First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
暂无分享,去创建一个
T. Bauknecht | W. Kuhn | A. du Bois | H. Lück | W. Meier | J. Pfisterer | B. Richter | J. Quaas
[1] M. Untch,et al. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. , 1997, Seminars in oncology.
[2] C. Tibaldi,et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L J Liang,et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Gehl,et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. Ozols,et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[7] A. Caraceni,et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Gore,et al. Impact of doxorubicin on survival in advanced ovarian cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Fanning,et al. Meta-Analysis of Cisplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin and Cyclophosphamide Chemotherapy of Ovarian Carcinoma , 1992, Obstetrics and gynecology.
[10] R. O’Toole,et al. Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian Carcinoma: A Multicenter Trial , 1992, American journal of clinical oncology.
[11] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Roger W. Jelliffe,et al. Creatinine Clearance: Bedside Estimate , 1973 .
[13] M. Forni,et al. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. , 1995, European journal of gynaecological oncology.
[14] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.